Skip to main content
SLNO
NASDAQ Life Sciences

Soleno 在 Neurocrine 收购之前撤回了 Vykat XR 的欧盟药物申请

feedReported by Reuters
Sentiment info
Negative
Importance info
7
Price
$52.255
Mkt Cap
$2.698B
52W Low
$29.43
52W High
$90.32
Market data snapshot near publication time

summarizeSummary

Soleno Therapeutics 自愿撤回了其罕见代谢障碍药物 Vykat XR 的欧洲营销申请，该药物用于治疗普拉德威利综合征。这种战略决策是在 Neurocrine Biosciences 最近宣布的收购之后做出的，Neurocrine Biosciences 计划专注于该药物在美国市场的销售。撤回申请消除了 Vykat XR 在欧洲市场可能带来的重大未来收入来源，阐明了 Neurocrine 收购后的这一关键资产的战略。虽然收购本身是主要的市场驱动因素，但这一消息对 Vykat XR 的未来商业化路径提供了重要的细节。投资者现在将专注于 Neurocrine 收购的成功完成以及 Vykat XR 在美国市场的执行情况。

在该公告发布时，SLNO的交易价格为$52.26，交易所为NASDAQ，所属行业为Life Sciences，市值约为$27亿。 52周交易区间为$29.43至$90.32。 这则新闻被评估为消极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed SLNO - Latest Insights

SLNO
Apr 28, 2026, 7:30 AM EDT
Filing Type: SC 14D9/A
Importance Score:
9
HSR Waiting Period Expires for Neurocrine's Acquisition of Soleno Therapeutics
Sentiment: Positive
View Wiseek Article
SLNO
Apr 28, 2026, 7:30 AM EDT
Filing Type: SC TO-T/A
Importance Score:
9
Neurocrine Biosciences Tender Offer for Soleno Therapeutics Clears HSR Regulatory Hurdle
Sentiment: Positive
View Wiseek Article
SLNO
Apr 20, 2026, 8:53 AM EDT
Filing Type: SC 14D9
Importance Score:
10
Soleno Board Unanimously Recommends Shareholders Accept Neurocrine's $53.00/Share All-Cash Tender Offer
Sentiment: Positive
View Wiseek Article
SLNO
Apr 20, 2026, 7:36 AM EDT
Filing Type: SC TO-T
Importance Score:
10
Neurocrine Biosciences Commences Tender Offer to Acquire Soleno Therapeutics for $53.00 Per Share in Cash
Sentiment: Positive
View Wiseek Article
SLNO
Apr 07, 2026, 1:15 PM EDT
Source: Reuters
Importance Score:
7
Soleno Withdraws EU Drug Application for Vykat XR Ahead of Neurocrine Acquisition
Sentiment: Negative
View Wiseek Article
SLNO
Apr 06, 2026, 5:08 PM EDT
Filing Type: SC TO-C
Importance Score:
10
Soleno Therapeutics to be Acquired by Neurocrine Biosciences for $2.9 Billion in All-Cash Tender Offer
Sentiment: Positive
View Wiseek Article
SLNO
Apr 06, 2026, 7:46 AM EDT
Filing Type: 8-K
Importance Score:
10
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash at $53.00 Per Share
Sentiment: Positive
View Wiseek Article
SLNO
Apr 06, 2026, 7:39 AM EDT
Filing Type: SC TO-C
Importance Score:
10
Soleno Therapeutics to be Acquired by Neurocrine Biosciences for $2.9 Billion in All-Cash Deal
Sentiment: Positive
View Wiseek Article
SLNO
Apr 06, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Neurocrine to Acquire Soleno Therapeutics, Bolstering Rare Disease Portfolio
Sentiment: Positive
View Wiseek Article
SLNO
Mar 16, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
7
Soleno Therapeutics Amends Bylaws, Tightening Shareholder Proposal Rules and Adding Forum Selection
Sentiment: Neutral
View Wiseek Article